search
Back to results

Low Dose Dexmedetomidine and Delirium After Cardiac Surgery (LOWDEXDEL)

Primary Purpose

Cardiac Surgical Procedures

Status
Completed
Phase
Phase 4
Locations
Belgium
Study Type
Interventional
Intervention
Dexmedetomidine
Placebo
Sponsored by
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Cardiac Surgical Procedures

Eligibility Criteria

60 Years - 90 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patients undergoing cardiac surgery with cardiopulmonary bypass

Exclusion Criteria:

  • Hepatic dysfunction (hepatic function tests 3 times the normal value)
  • Preoperative renal replacement therapy
  • Preoperative delirium
  • Emergency surgery not allowing neurologic evaluation by MMSE
  • Mini invasive cardiac surgery
  • Patients not speaking French

Sites / Locations

  • Cliniques Universitaires Saint Luc

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Placebo Comparator

Arm Label

Dexmedetomidine

Placebo

Arm Description

Dexmedetomidine will be administered at 0.4ug/kg/h (5mL/h) starting at the closure of the chest and continued during 10h.

NaCl 0.9% will be administered at 5mL/h starting at the closure of the chest and continued during 10h.

Outcomes

Primary Outcome Measures

The incidence of delirium
The incidence of delirium detected by means of CAM-ICU and CAM

Secondary Outcome Measures

Number of days spent in delirium
Total number of days in a delirious state
ICU stay
The duration of days admitted in the ICU and in the hospital
Total dose of analgesics
Total dose of analgesics used in the ICU
Total dose of vasopressors
Total dose of vasopressors used in the ICU
Pace maker necessitation
Number of patients needing external pacing
Hospital stay
The duration of days admitted in the hospital
Total dose sedatives
Total dose of sedatives used in the ICU
Total dose of inotropic agents
Total dose of inotropic agents used in the ICU

Full Information

First Posted
August 1, 2017
Last Updated
September 28, 2020
Sponsor
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
search

1. Study Identification

Unique Protocol Identification Number
NCT03388541
Brief Title
Low Dose Dexmedetomidine and Delirium After Cardiac Surgery
Acronym
LOWDEXDEL
Official Title
Does LOW Dose DEXmedetomidine After Cardiopulmonary Bypass Separation Decrease the Incidence of DELirium: A Double-blind Randomized Placebo-controlled Study (LOWDEXDEL Study)
Study Type
Interventional

2. Study Status

Record Verification Date
September 2020
Overall Recruitment Status
Completed
Study Start Date
January 17, 2018 (Actual)
Primary Completion Date
August 12, 2019 (Actual)
Study Completion Date
August 12, 2019 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Cliniques universitaires Saint-Luc- Université Catholique de Louvain

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Delirium after cardiac surgery can occur in up to 50% of the patients and has been shown to be significantly associated with increased morbidity and mortality. Advanced age is a significant risk factor of delirium. Numerous studies have shown that sedation with high doses of Dexmedetomidine in the ICU reduces the incidence of postoperative delirium. On the other hand animal studies have shown neuroprotective effects of Dexmedetomidine by means of stimulating alpha2A-adrenoceptors. It is not clear whether the administration of a low dose Dexmedetomidine in cardiac surgery would have any neuroprotective effects by stimulating the alpha 2A-receptors and as such would decrease the incidence of postoperative delirium.
Detailed Description
Postoperative delirium (PD) is a common problem in cardiac surgical patients. Its incidence varies among studies and can reach up to 50% of the patients. PD is associated with increased morbidity and mortality. Its occurrence is the resultant between the predisposing factors and the precipitating factors. Age seems to be a significant predisposing factor. In this regard the pathophysiology of PD is not yet fully understood. There are several hypothetical mechanisms for the development of PD. The first hypothesis is cerebral ischemia and BBB breakdown. The second hypothesis is neuro-inflammation. Peripheral pro-inflammatory mediators especially released during surgery would interact with the brain. Otherwise there is the problem of sleep deprivation/fragmentation in patients admitted to the hospital. Dexmedetomidine is a potent and more selective alpha2-adrenergic receptor than clonidine. Studies have demonstrated that it has neuroprotective and anti-inflammatory actions. Numerous studies including trials in cardiac surgery have shown a decreased incidence of delirium when Dexmedetomidine was used as sedative in the ICU compared with other sedatives acting on the GABA receptors. However, in these studies high doses of Dexmedetomidine were used for periods up to 24h. Dexmedetomidine was started in the ICU and was not compared in a double-blind fashion with placebo. In a recent randomized double-blind placebo-controlled trial a very low dose of Dexmedetomidine decreased the occurrence of PD when compared to placebo. However this study was performed in non-cardiac patients. Moreover the patients were included after their arrival in the ICU, which means that those patients who were intubated at their arrival in the ICU were not included. And again the study medication was only started after arrival in the ICU. The aim of this study is to elucidate whether the administration of Dexmedetomidine at a low dose would decrease the incidence of PD in elderly patients undergoing cardiac surgery. The hypothesis is that Dexmedetomidine at low doses, by only stimulating the alpha2A adrenoceptors,would have neuroprotective affects ans as such decrease the incidence of PD. Dexmedetomidine would also have anti-inflammatory effects and effects on the quality of sleep. Both mechanisms would play a role in the pathophysiology of PD.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cardiac Surgical Procedures

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
420 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Dexmedetomidine
Arm Type
Active Comparator
Arm Description
Dexmedetomidine will be administered at 0.4ug/kg/h (5mL/h) starting at the closure of the chest and continued during 10h.
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
NaCl 0.9% will be administered at 5mL/h starting at the closure of the chest and continued during 10h.
Intervention Type
Drug
Intervention Name(s)
Dexmedetomidine
Intervention Description
Dexmedetomidine will be started at 5mL/h while the patient is still in the operating room. The patient will be transferred to the intensive care unit with a sedative regimen based on propofol.
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
A continuous infusion of NaCL 0.9% will be started at 5mL/h while the patient is still in the operating room. The patient will be transferred to the intensive care unit with a sedative regimen based on propofol.
Primary Outcome Measure Information:
Title
The incidence of delirium
Description
The incidence of delirium detected by means of CAM-ICU and CAM
Time Frame
Through study completion, an average of 30 days
Secondary Outcome Measure Information:
Title
Number of days spent in delirium
Description
Total number of days in a delirious state
Time Frame
Through study completion, an average of 30 days
Title
ICU stay
Description
The duration of days admitted in the ICU and in the hospital
Time Frame
Through study completion, an average of 30 days
Title
Total dose of analgesics
Description
Total dose of analgesics used in the ICU
Time Frame
Through study completion, an average of 30 days
Title
Total dose of vasopressors
Description
Total dose of vasopressors used in the ICU
Time Frame
Through study completion, an average of 30 days
Title
Pace maker necessitation
Description
Number of patients needing external pacing
Time Frame
Through study completion, an average of 30 days
Title
Hospital stay
Description
The duration of days admitted in the hospital
Time Frame
Through study completion, an average of 30 days
Title
Total dose sedatives
Description
Total dose of sedatives used in the ICU
Time Frame
Through study completion, an average of 30 days
Title
Total dose of inotropic agents
Description
Total dose of inotropic agents used in the ICU
Time Frame
Through study completion, an average of 30 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
60 Years
Maximum Age & Unit of Time
90 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients undergoing cardiac surgery with cardiopulmonary bypass Exclusion Criteria: Hepatic dysfunction (hepatic function tests 3 times the normal value) Preoperative renal replacement therapy Preoperative delirium Emergency surgery not allowing neurologic evaluation by MMSE Mini invasive cardiac surgery Patients not speaking French
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Mona Momeni, MD,PhD
Organizational Affiliation
Cliniques universitaires Saint-Luc
Official's Role
Principal Investigator
Facility Information:
Facility Name
Cliniques Universitaires Saint Luc
City
Brussels
ZIP/Postal Code
1200
Country
Belgium

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
16428542
Citation
Paris A, Mantz J, Tonner PH, Hein L, Brede M, Gressens P. The effects of dexmedetomidine on perinatal excitotoxic brain injury are mediated by the alpha2A-adrenoceptor subtype. Anesth Analg. 2006 Feb;102(2):456-61. doi: 10.1213/01.ane.0000194301.79118.e9.
Results Reference
background
PubMed Identifier
8102042
Citation
Maier C, Steinberg GK, Sun GH, Zhi GT, Maze M. Neuroprotection by the alpha 2-adrenoreceptor agonist dexmedetomidine in a focal model of cerebral ischemia. Anesthesiology. 1993 Aug;79(2):306-12. doi: 10.1097/00000542-199308000-00016.
Results Reference
background
PubMed Identifier
28625441
Citation
Jiang L, Hu M, Lu Y, Cao Y, Chang Y, Dai Z. The protective effects of dexmedetomidine on ischemic brain injury: A meta-analysis. J Clin Anesth. 2017 Aug;40:25-32. doi: 10.1016/j.jclinane.2017.04.003. Epub 2017 Apr 17.
Results Reference
background
PubMed Identifier
19833271
Citation
Tasdogan M, Memis D, Sut N, Yuksel M. Results of a pilot study on the effects of propofol and dexmedetomidine on inflammatory responses and intraabdominal pressure in severe sepsis. J Clin Anesth. 2009 Sep;21(6):394-400. doi: 10.1016/j.jclinane.2008.10.010.
Results Reference
background
PubMed Identifier
27542303
Citation
Su X, Meng ZT, Wu XH, Cui F, Li HL, Wang DX, Zhu X, Zhu SN, Maze M, Ma D. Dexmedetomidine for prevention of delirium in elderly patients after non-cardiac surgery: a randomised, double-blind, placebo-controlled trial. Lancet. 2016 Oct 15;388(10054):1893-1902. doi: 10.1016/S0140-6736(16)30580-3. Epub 2016 Aug 16.
Results Reference
background
PubMed Identifier
19786862
Citation
Shehabi Y, Grant P, Wolfenden H, Hammond N, Bass F, Campbell M, Chen J. Prevalence of delirium with dexmedetomidine compared with morphine based therapy after cardiac surgery: a randomized controlled trial (DEXmedetomidine COmpared to Morphine-DEXCOM Study). Anesthesiology. 2009 Nov;111(5):1075-84. doi: 10.1097/ALN.0b013e3181b6a783.
Results Reference
background
PubMed Identifier
26575144
Citation
Djaiani G, Silverton N, Fedorko L, Carroll J, Styra R, Rao V, Katznelson R. Dexmedetomidine versus Propofol Sedation Reduces Delirium after Cardiac Surgery: A Randomized Controlled Trial. Anesthesiology. 2016 Feb;124(2):362-8. doi: 10.1097/ALN.0000000000000951.
Results Reference
background
PubMed Identifier
33358336
Citation
Momeni M, Khalifa C, Lemaire G, Watremez C, Tircoveanu R, Van Dyck M, Kahn D, Rosal Martins M, Mastrobuoni S, De Kerchove L, Zango SH, Jacquet LM. Propofol plus low-dose dexmedetomidine infusion and postoperative delirium in older patients undergoing cardiac surgery. Br J Anaesth. 2021 Mar;126(3):665-673. doi: 10.1016/j.bja.2020.10.041. Epub 2020 Dec 24.
Results Reference
derived

Learn more about this trial

Low Dose Dexmedetomidine and Delirium After Cardiac Surgery

We'll reach out to this number within 24 hrs